Literature DB >> 21472758

Estimating transformations for repeated measures modeling of continuous bounded outcome data.

Matthew M Hutmacher1, Jonathan L French, Sriram Krishnaswami, Sujatha Menon.   

Abstract

Continuous bounded outcome data are unlikely to meet the usual assumptions for mixed-effects models of normally distributed and independent subject-specific and residual random effects. Additionally, overly complicated model structures might be necessary to account adequately for non-drug (time-dependent) and drug treatment effects. A transformation strategy with a likelihood component for censoring is developed to promote the simplicity of model structures and to improve the plausibility of assumptions on the random effects. The approach is motivated by Health Assessment Questionnaire Disability Index (HAQ-DI) data from a study in subjects with rheumatoid arthritis and is evaluated using a simulation study.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21472758     DOI: 10.1002/sim.4155

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  15 in total

1.  Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.

Authors:  Chuanpu Hu; Bruce Randazzo; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-20       Impact factor: 2.745

2.  Response to Letter to the Editor by Joe Brew, Department of Epidemiology, University of Florida.

Authors:  M Pia Chaparro; Shannon E Whaley; Catherine M Crespi; Maria Koleilat; Tabashir Z Nobari; Edmund Seto; May C Wang
Journal:  J Epidemiol Community Health       Date:  2015-01-23       Impact factor: 3.710

Review 3.  On the Comparison of Methods in Analyzing Bounded Outcome Score Data.

Authors:  Chuanpu Hu
Journal:  AAPS J       Date:  2019-08-26       Impact factor: 4.009

4.  Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.

Authors:  Chuanpu Hu; Omoniyi J Adedokun; Liping Zhang; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

5.  Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database.

Authors:  K Ito; M M Hutmacher; B W Corrigan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-09-19       Impact factor: 2.745

6.  Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint.

Authors:  Chuanpu Hu; Philippe O Szapary; Alan M Mendelsohn; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-07-20       Impact factor: 2.745

7.  Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease.

Authors:  Xu Steven Xu; Mahesh Samtani; Min Yuan; Partha Nandy
Journal:  AAPS J       Date:  2014-08-28       Impact factor: 4.009

8.  Applying Beta Distribution in Analyzing Bounded Outcome Score Data.

Authors:  Chuanpu Hu; Honghui Zhou; Amarnath Sharma
Journal:  AAPS J       Date:  2020-03-17       Impact factor: 4.009

9.  Bounded outcome score modeling: application to treating psoriasis with ustekinumab.

Authors:  Chuanpu Hu; Newman Yeilding; Hugh M Davis; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-06-18       Impact factor: 2.745

10.  Development of a placebo effect model combined with a dropout model for bipolar disorder.

Authors:  Wan Sun; Thomas P Laughren; Hao Zhu; Guenther Hochhaus; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-03-02       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.